Pertuxumab (Perjeta)

This slideshow reviews Pertuxumab (Perjeta) for the treatment of HER2-positive metastatic breast cancer in combination with trastuzumab (Herceptin) and docetaxel (Docefrez, Taxotere, generics) in patients who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.